Our innovative business model uses advanced analytics on large volumes of real world, clinically relevant patient health data collected from hospital centers where tumor biomarker testing has been used for many years.

We believe much of the innovation in cancer diagnostics for the coming decade will come from applying powerful data analytics to proven cancer biomarkers.

20/20 is using the power of realworld data and powerful A.I. driven algorithms to drive development of new tests for early detection of cancers that are affordable and accessible to hospitals all over the world.